Physician profile
Kevin E Dougherty
NPI 1922186998
$2,549.52
in general payments reported to CMS, 2019-2025
25 companies · $74.47 in 2025
The $74.47 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,047 · 2020: $189 · 2021: $87.31 · 2022: $130 · 2023: $523 · 2024: $499 · 2025: $74.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,096.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,095.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $495.08 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $299.09 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $252.79 | 2019-2024 | Evenity, Prolia |
| Janssen Pharmaceuticals, INC | $169.88 | 2019-2020 | |
| Astellas Pharma US INC | $169.25 | 2019-2024 | Veozah, Myrbetriq |
| Abbott Laboratories | $167.06 | 2023-2025 | Proclaim, Freestyle Libre 3, Eterna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.61 | 2019-2024 | Jardiance |
| Pfizer INC. | $136.44 | 2019-2023 | |
| Daiichi Sankyo INC. | $101.52 | 2019-2024 | Injectafer |
| Abbvie INC. | $66.71 | 2023-2025 | Qulipta, Ubrelvy |
| Ferring Pharmaceuticals INC. | $61.05 | 2023 | Rebyota |
| Glaxosmithkline, LLC. | $58.28 | 2022-2024 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $55.05 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Novartis Pharmaceuticals Corporation | $51.35 | 2022-2023 | |
| Amarin Pharma, INC. | $46.26 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.23 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $38.19 | 2021 | |
| Phadia US INC. | $36.63 | 2022-2024 | Immunocap |
| Allergan, INC. | $32.03 | 2019-2020 | |
| Grifols USA, LLC | $24.49 | 2019-2024 | Prolastin-C Liquid |
| Gilead Sciences, INC. | $21.77 | 2019 | |
| Eisai INC. | $18.92 | 2024 | |
| Shionogi INC | $17.52 | 2019 | |
| Edwards Lifesciences Corporation | $16.38 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Sanofi Pasteur INC. | $14.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Dougherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.